SURFACE LOGIX INC. TO PRESENT AT BIO CEO & INVESTOR CONFERENCE 2007

BOSTON, Mass. (February  8, 2007) – Surface Logix Inc. announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the company’s drug development pipeline at the upcoming BIO CEO & Investor Conference on February 13, 2007, at 4:30 p.m. Eastern time from Waldorf-Astoria Hotel in New York City.   

Surface Logix Inc. currently has two programs in human clinical trials with a third program approaching its initial regulatory submission.  Mr. Mahoney will discuss the latest results for SLx-2101, currently in Phase IIa, a second generation PDE5 inhibitor designed to address cardiovascular indications, including Raynaud’s Syndrome and Hypertension; and SLx-4090, soon to be in Phase IIa, a first-in-class enterocyte specific MTP inhibitor targeting unmet needs in dyslipidemia, metabolic disorders and obesity.

About Surface Logix Inc.

Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.

Contact:
Warwick Tong
Senior Vice President, Commercial Development
617.746.8500

Media:
Kari Watson
MacDougall Biomedical Communications Inc.
508.647.0209